Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis From IMbark Versus Real-World Data and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow-Up

Rytelo (imetelstat) - Geron

Inrebic (fedratinib) - BMS

Jakafi (ruxolitinib) - Incyte

https://www.sciencedirect.com/science/article/abs/pii/S2152265026023207

Andrew T Kuykendall MD 1; Hana Qasim MBBS 1; Ghada Araji MD 1; Libo Sun PhD 2; Qi Xia PhD 2; Michelle Mudge-Riley DOMHARDN 2; Joseph Eid MD 2; Rami S Komrokji MD 1

Sep 1, 2026